New York State Common Retirement Fund Sells 9,612 Shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO)

New York State Common Retirement Fund lowered its position in shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO) by 16.4% during the third quarter, HoldingsChannel.com reports. The fund owned 49,137 shares of the company’s stock after selling 9,612 shares during the quarter. New York State Common Retirement Fund’s holdings in Allogene Therapeutics were worth $1,263,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. First Trust Advisors LP boosted its position in Allogene Therapeutics by 0.4% during the first quarter. First Trust Advisors LP now owns 101,816 shares of the company’s stock valued at $2,944,000 after acquiring an additional 375 shares during the last quarter. Vident Investment Advisory LLC raised its holdings in shares of Allogene Therapeutics by 1.8% during the second quarter. Vident Investment Advisory LLC now owns 60,621 shares of the company’s stock valued at $1,581,000 after purchasing an additional 1,057 shares during the period. State Board of Administration of Florida Retirement System raised its holdings in shares of Allogene Therapeutics by 5.0% during the second quarter. State Board of Administration of Florida Retirement System now owns 22,684 shares of the company’s stock valued at $592,000 after purchasing an additional 1,087 shares during the period. Teacher Retirement System of Texas raised its holdings in shares of Allogene Therapeutics by 18.8% during the second quarter. Teacher Retirement System of Texas now owns 7,815 shares of the company’s stock valued at $204,000 after purchasing an additional 1,235 shares during the period. Finally, Lazard Asset Management LLC acquired a new position in shares of Allogene Therapeutics during the second quarter valued at about $48,000. 76.34% of the stock is currently owned by institutional investors and hedge funds.

In other news, Director Arie Belldegrun acquired 155,039 shares of Allogene Therapeutics stock in a transaction on Wednesday, January 12th. The stock was acquired at an average cost of $12.60 per share, with a total value of $1,953,491.40. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 26.30% of the company’s stock.

Several equities analysts have recently weighed in on the stock. Royal Bank of Canada dropped their price objective on shares of Allogene Therapeutics from $45.00 to $35.00 and set an “outperform” rating on the stock in a report on Tuesday, December 14th. They noted that the move was a valuation call. JMP Securities reiterated a “buy” rating and set a $27.00 price objective on shares of Allogene Therapeutics in a report on Friday, December 17th. Roth Capital dropped their price objective on shares of Allogene Therapeutics from $60.00 to $35.00 and set a “buy” rating on the stock in a report on Friday, October 8th. Bank of America dropped their price objective on shares of Allogene Therapeutics from $41.00 to $32.00 and set a “buy” rating on the stock in a report on Friday, October 8th. Finally, Raymond James upgraded shares of Allogene Therapeutics from a “market perform” rating to an “outperform” rating and set a $36.00 target price on the stock in a report on Thursday, September 23rd. Two investment analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company. According to data from MarketBeat.com, Allogene Therapeutics has a consensus rating of “Buy” and an average price target of $35.40.

Shares of ALLO stock opened at $13.28 on Friday. Allogene Therapeutics, Inc. has a 52-week low of $11.54 and a 52-week high of $39.12. The company has a 50-day simple moving average of $16.53 and a two-hundred day simple moving average of $20.27. The company has a market capitalization of $1.89 billion, a price-to-earnings ratio of -7.06 and a beta of 0.71.

Allogene Therapeutics (NASDAQ:ALLO) last issued its quarterly earnings data on Thursday, November 4th. The company reported ($0.57) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.56) by ($0.01). The business had revenue of $0.05 million for the quarter. During the same period in the prior year, the business posted ($0.52) earnings per share. As a group, research analysts predict that Allogene Therapeutics, Inc. will post -1.98 earnings per share for the current fiscal year.

Allogene Therapeutics Company Profile

Allogene Therapeutics, Inc operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The firm develops a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells.

Featured Story: How Do You Make Money With Penny Stocks?

Want to see what other hedge funds are holding ALLO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allogene Therapeutics, Inc. (NASDAQ:ALLO).

Institutional Ownership by Quarter for Allogene Therapeutics (NASDAQ:ALLO)

Receive News & Ratings for Allogene Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allogene Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.